-
Dancing With a Stranger: Understanding Apathy in Huntington’s Disease Through Caregivers
Latest News
-
Huntington's Disease Therapeutics Conference 2014: day 3
Biomarkers and preparing for trials: the third & final day of the 2014 Huntington's Disease Therapeutics Conference
-
Huntington's Disease Therapeutics Conference 2014: day 2
Cells, circuits and systems: day 2 of the 2014 HD Therapeutics conference
-
Huntington's Disease Therapeutics Conference 2014: day 1
HDBuzz reports from the opening day of science sessions at the 2014 HD Therapeutics Conference in Palm Springs.
-
Prana announces results of Reach2HD trial of PBT2 for Huntington's disease
Results are in for a clinical trial testing the drug PBT2 for HD. Are the claims in the announcement justified?
-
Does high-dose creatine "slow the onset" of Huntington's Disease?
A new study claims that high-dose creatine "slows the onset of Huntington Disease". How much hope and how much hype?
-
Joint HDBuzz Prizewinner: Yeast studies suggest a new way to protect cells from 'oxidative damage'
Researchers identify Gpx1, a protein that may be protective in HD. An existing drug can mimic its antioxidant effect.
-
Joint HDBuzz Prizewinner: Pennies for your neurons — copper’s bad influence on Huntington’s disease
There is copper in your brain! Check out how copper and the Huntington’s disease protein are partners in crime.
-
Could a 'brain shuttle' get Huntington's disease drugs to where they're needed?
Roche's 'brain shuttle' sneaks drugs past the blood-brain barrier. Could it work for HD gene silencing drugs?
-
Is a new Huntington’s Disease drug study on the right Trk?
A recent HD animal study reveals that a small molecule drug could be an effective “Trk” to target for HD therapeutics
-
DNA shutdown proteins in Huntington's disease: More than meets the eye
Blocking HDAC4 improves Huntington's disease-related problems in cells and mice – but in a surprising way
HDBuzz Trial Tracker
Sites for Phase 3 trial for votoplam, INVEST-HD, now open. Updates on recruitment and first dosing imminent.
Progress update for NCT06585449 – A Study to Evaluate ALN-HTT02
